294 related articles for article (PubMed ID: 36825029)
41. Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches.
Menyhárt O; Győrffy B
Cancer Metastasis Rev; 2020 Mar; 39(1):211-233. PubMed ID: 31970590
[TBL] [Abstract][Full Text] [Related]
42. Profiling targetable immune checkpoints in osteosarcoma.
McEachron TA; Triche TJ; Sorenson L; Parham DM; Carpten JD
Oncoimmunology; 2018; 7(12):e1475873. PubMed ID: 30524885
[TBL] [Abstract][Full Text] [Related]
43. Immune Checkpoint-Associated Locations of Diffuse Gliomas Comparing Pediatric With Adult Patients Based on Voxel-Wise Analysis.
Zhang L; Zhang B; Dou Z; Wu J; Iranmanesh Y; Jiang B; Sun C; Zhang J
Front Immunol; 2021; 12():582594. PubMed ID: 33815356
[No Abstract] [Full Text] [Related]
44. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
45. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
46. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
47. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
[TBL] [Abstract][Full Text] [Related]
48. Expression of GNAS, TP53, and PTEN Improves the Patient Prognostication in Sonic Hedgehog (SHH) Medulloblastoma Subgroup.
da Silva LS; Mançano BM; de Paula FE; Dos Reis MB; de Almeida GC; Matsushita M; Junior CA; Evangelista AF; Saggioro F; Serafini LN; Stavale JN; Malheiros SMF; Lima M; Hajj GNM; de Lima MA; Taylor MD; Leal LF; Reis RM
J Mol Diagn; 2020 Jul; 22(7):957-966. PubMed ID: 32380172
[TBL] [Abstract][Full Text] [Related]
49. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.
Gorris MAJ; Halilovic A; Rabold K; van Duffelen A; Wickramasinghe IN; Verweij D; Wortel IMN; Textor JC; de Vries IJM; Figdor CG
J Immunol; 2018 Jan; 200(1):347-354. PubMed ID: 29141863
[TBL] [Abstract][Full Text] [Related]
50. Immune gene expression in head and neck squamous cell carcinoma patients.
Lecerf C; Kamal M; Vacher S; Chemlali W; Schnitzler A; Morel C; Dubot C; Jeannot E; Meseure D; Klijanienko J; Mariani O; Borcoman E; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Choussy O; Hoffmann C; Piaggio E; Bieche I; Le Tourneau C
Eur J Cancer; 2019 Nov; 121():210-223. PubMed ID: 31593831
[TBL] [Abstract][Full Text] [Related]
51. Lack of KBTBD4 Mutations in Molecularly Classified Brazilian Medulloblastomas.
Leal LF; Cavagna RO; Campanella NC; Mançano B; Almeida GC; Matsushita M; Almeida Junior CR; Saggioro F; Stavale JN; Malheiros SMF; Lima M; Hajj GNM; Neder L; Reis RM
J Neuropathol Exp Neurol; 2019 Sep; 78(9):788-790. PubMed ID: 31403685
[TBL] [Abstract][Full Text] [Related]
52. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
Zhukova N; Ramaswamy V; Remke M; Pfaff E; Shih DJ; Martin DC; Castelo-Branco P; Baskin B; Ray PN; Bouffet E; von Bueren AO; Jones DT; Northcott PA; Kool M; Sturm D; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognar L; Klekner A; Cho BK; Kim SK; Wang KC; Eberhart CG; Fevre-Montange M; Fouladi M; French PJ; Kros M; Grajkowska WA; Gupta N; Weiss WA; Hauser P; Jabado N; Jouvet A; Jung S; Kumabe T; Lach B; Leonard JR; Rubin JB; Liau LM; Massimi L; Pollack IF; Shin Ra Y; Van Meir EG; Zitterbart K; Schüller U; Hill RM; Lindsey JC; Schwalbe EC; Bailey S; Ellison DW; Hawkins C; Malkin D; Clifford SC; Korshunov A; Pfister S; Taylor MD; Tabori U
J Clin Oncol; 2013 Aug; 31(23):2927-35. PubMed ID: 23835706
[TBL] [Abstract][Full Text] [Related]
53. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
[TBL] [Abstract][Full Text] [Related]
54. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
[TBL] [Abstract][Full Text] [Related]
55. Expression patterns of immune checkpoints in acute myeloid leukemia.
Chen C; Liang C; Wang S; Chio CL; Zhang Y; Zeng C; Chen S; Wang C; Li Y
J Hematol Oncol; 2020 Apr; 13(1):28. PubMed ID: 32245463
[TBL] [Abstract][Full Text] [Related]
56. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
Front Immunol; 2021; 12():705378. PubMed ID: 34526987
[TBL] [Abstract][Full Text] [Related]
57. Identification of CD24 as a marker of Patched1 deleted medulloblastoma-initiating neural progenitor cells.
Robson JP; Remke M; Kool M; Julian E; Korshunov A; Pfister SM; Osborne GW; Taylor MD; Wainwright B; Reynolds BA
PLoS One; 2019; 14(1):e0210665. PubMed ID: 30657775
[TBL] [Abstract][Full Text] [Related]
58. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors.
Melaiu O; Lucarini V; Giovannoni R; Fruci D; Gemignani F
Semin Cancer Biol; 2022 Feb; 79():18-43. PubMed ID: 32659257
[TBL] [Abstract][Full Text] [Related]
59. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
[TBL] [Abstract][Full Text] [Related]
60. PRAME gene expression profile in medulloblastoma.
Vulcani-Freitas TM; Saba-Silva N; Cappellano A; Cavalheiro S; Toledo SR
Arq Neuropsiquiatr; 2011 Feb; 69(1):9-12. PubMed ID: 21359415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
